Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Outlook Therapeutics ( (OTLK) ) is now available.
On March 5, 2026, Outlook Therapeutics reported it had held a Type A meeting with the U.S. Food and Drug Administration to address a December 30, 2025 complete response letter for its biologics license resubmission for ONS-5010/LYTENAVA™, an investigational bevacizumab formulation for wet AMD. The discussion focused on clarifying the FDA’s concerns over substantial evidence of effectiveness, with the company seeking alignment on confirmatory data and the most efficient pathway to potential U.S. approval.
Outlook highlighted that ONS-5010 achieved statistically significant visual acuity gains in its NORSE TWO Phase 3 trial and showed supportive efficacy and safety data from NORSE EIGHT and other studies, with no safety issues flagged by regulators. If ultimately approved in the United States, ONS-5010 would become the first FDA-approved ophthalmic bevacizumab product for retinal indications, backed by a fully domestic manufacturing supply chain, a development that could reshape the treatment landscape for wet AMD and formalize a drug class long used off-label.
The most recent analyst rating on (OTLK) stock is a Sell with a $0.39 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Underperform.
The score is weighed down primarily by very weak financial performance (large losses, negative equity, and heavy cash burn). Technicals also remain bearish with price below all major moving averages and negative MACD. Negative corporate events (Nasdaq bid-price noncompliance and an FDA CRL) add further risk, while valuation provides limited support given the negative P/E and no dividend.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA™, an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration. The company has begun commercial launches of LYTENAVA™ in Germany, Austria and the UK following marketing authorizations in the EU and UK.
Average Trading Volume: 5,718,190
Technical Sentiment Signal: Sell
Current Market Cap: $35.02M
Learn more about OTLK stock on TipRanks’ Stock Analysis page.